GSK Related Rumors
-
Optimer Pharma (OPTR) Said to Draw Interest from Glaxo (GSK), Astellas
-
Acquisition of Theravance (THRX) Might be Best Option for Glaxo (GSK)
-
InterMune (ITMN) Could Draw Bids as IPF Treatment Esbriet Gains Strength
-
Amarin (AMRN) Ramps as BASF's Pronova Takeover Highlights Value
-
Human Genome Sciences (HGSI) Agrees to $14/Share Takeover from GSK (GSK) - Reports
-
Arena Pharma (ARNA) Higher as M&A Chatter Heats Up
-
A Celgene (CELG) / Human Genome Sciences (HGSI) Deal Seen as Unlikely
-
Human Genome (HGSI) Could Get 15% More in Takeover Bid - Analyst
-
BioMarin (BMRN) Moves on Renewed Takeover Chatter
-
Is Human Genome (HGSI) Getting Desperate for a Deal?
-
Piper Jaffray Says BioMarin (BMRN) Could Be Taken Out for $52-$70/Share
-
BioMarin (BMRN) Higher as Takeover Chatter Swirls
-
Human Genome (HGSI) Shares Moving as Reuters Says Glaxo (GSK) Wants to Replace Entire Board
-
Human Genome Sciences (HGSI) Unanimously Rejects GlaxoSmithKline (GSK) Offer
-
GlaxoSmithKline (GSK) Commence $13/Share Tender Offer for Human Genome Sciences (HGSI)
-
Glaxo's Bid for Human Genome Is a Positive for Anthera Pharma (ANTH) - Analyst
-
Human Genome (HGSI) Trades Well Above GSK Offer, Other Biotechs See Action
-
UPDATE - UBS Initiates Coverage on Human Genome (HGSI) with a Neutral; See Stock Range-Bound as GSK Hovers
-
GlaxoSmithKline (GSK) Seeking Buyer for European Non-Core Drugs Portfolio -IBT
-
Piper Jaffray Sees Human Genome (HGSI) Selling for $21-$26/Share in Takeover
-
Glaxo (GSK) Could Bid $25/Share for Human Genome (HGSI) -UK's Mail
-
Shares of Anadys (ANDS) Trade Above $1; Analyst Believes Co. Could Get a Bid Following Setrobuvir Data
-
Human Genome (HGSI) Could Become Takeover Target Upon Approval of Benlysta
-
Savient Pharmaceuticals (SVNT) Continues Surge On Takeover Speculation
-
Leerink Swann Raises Target on Savient (SVNT) to $22; Highlights Takeover Potential Following Krystexxa Approval
-
Wall Street Hubbub 7/26: A Genzyme (GENZ) Deal Coming, Is Biogen Idec (BIIB) Next, New BP CEO, Goldman Sachs the Movie
-
Abraxis Bioscience (ABII) Reportedly Puts Itself Up for Sale
-
Piper Jaffray Assumes Coverage on Human Genome Sciences (HGSI) with an Overweight; Benlysta's First Mover Advantage Key to $4bn+ Opportunity
-
Goldman Sachs Resumes Human Genome Sciences (HGSI) at Buy, Sees As Potential Takeover Target
-
Human Genome (HGSI) Up On More Takeover Talk
-
Human Genome Sciences (HGSI) Climbs Higher On Takeover Speculation
-
Human Genome (HGSI) Shares Spike as GlaxoSmithKline (GSK) Rumored to Have $30/Share Bid Ready
-
Novartis (NVS), Sanofi-Aventis (SNY), Glaxo (GSK) to Receive $661M of $1B Set Side for Developing H1N1 Flu Vaccine -CNBC
-
Biogen Idec (BIIB) Rises On Renewed Takeover Talk
-
Allergan (AGN) call volume and volatility Spike on Speculation
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
-
Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
-
AstraZeneca (AZN) Up on Glaxosmithkline Buyout Chatter
-
Reports Glaxosmithkline's CEO No Comment on Biogen Idec (BIIB) Interest
-
Market Rumors 07/06
-
Is a Super-Secretive Hedge Fund Targeting Flamel Technologies (FLML) for Activism?
-
Needham Comments on Other Stocks in RNAi Following Merck's Deal to Buy Sirna Therapeutics
-
Bristol-Myers (BMY) and Schering-Plough (SGP) Higher On Rumored Deal
-
Sepracor (SEPR) Spokeswomen 'No Comment' On Takeover Talk, Shares Surge
-
Sepracor (SEPR) Sees Upside on Renewed Takeover Chatter
-
Serono (SRA) Sinks After Sales Process Ends Unsuccessfully
-
Reports GSK Restarts Talks for SRA
-
VRTX Seen As Possible Target for Merck
-
Citigroup Predicts SEPR Could Be A Takeover Target in 2006
-
SRA Held Talks with NVS, GSK, SNY and PFE - WSJ
Back to GSK Stock Lookup
